Last updated: November 22, 2023
Sponsor: Natalie Torok
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Liver Disease
Primary Biliary Cholangitis
Digestive System Neoplasms
Treatment
N/AClinical Study ID
NCT05165446
62249
Ages 18-99 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male or non-pregnant/non-lactating women ≥ 18 years of age
- Diagnosis of NASH
- Diagnosis of pre-cirrhotic fibrosis (F1-F3), diagnosed as per standard of care (history, exam, laboratory tests, Fibroscan, within 6 months of enrollment)
- Na-MELD < 9: The Na-MELD (sodium-Model for End Stage Liver Disease) score is routinelyused to assess liver synthetic function and life expectancy. Patients with Na-MELD<9have less than 1.9% 3 months liver-related mortality risk, and their liver syntheticfunction is normal.
- Groups both with and without T2DM will be enrolled.
- Women of childbearing potential must agree to at least two methods of contraception.
- Will not participate in any other clinical trial for the duration of the study
- Will not consume alcohol for the duration of the study
- If on vitamin E, pioglitazone or any anti diabetic treatment prior to the study, willhave been on stable therapies for 6 months prior to enrolment.
- Able to undergo 3 Tesla MRI and complete MRI screening form
- Ability to understand and the willingness to sign a written informed consent document.
- ECOG or Karnofsky Performance Status will be not be employed
Exclusion
Exclusion Criteria:
- Presence of any other form of liver disease, including viral hepatitis, autoimmunehepatitis, alcoholic liver disease, genetic causes of chronic liver disease,cardiogenic liver disease, and HIV positivity (can cause liver fibrosis).
- ALT>300 U/l
- Total serum bilirubin ≥ to 1.3 mg/dL (Gilbert's Syndrome patients are excepted)
- International Normalized Ratio (INR) ≥ 1.3
- MELD>9
- Serum creatinine >2.0mg/dl
- Known alcohol abuse or alcohol use disorder (AUDIT profile and/or pos. urineethylglucuronide):
- >20 g/day for women
- >30 g/day for men
- Active substance abuse
- Platelet count ≤100//mm3
- Hemoglobin <11 g/dl in females or <12 g/dl in males
- Presence/history of HCC, or other primary or metastatic cancer to the liver.
- History of liver transplantation
- History of bariatric surgery
- History of inflammatory bowel disease
- History of advanced pulmonary disease
- Any concerns regarding compliance by enrolling physician
- Pregnant or lactating women.
- Presence of cardiac implantable electronic device (CIED)
- History of CIED with retained leads
- Presence of any metallic foreign body that is unsafe for the MRI environment
- Inability to undergo MRI based on responses to the MRI screening form
- History of claustrophobia or the need for sedation to undergo MRI
Study Design
Total Participants: 35
Study Start date:
January 27, 2022
Estimated Completion Date:
March 31, 2024
Study Description
Connect with a study center
Stanford Hospital
Stanford, California 94305
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.